Lundbeck to present clinical and pre-clinical data on Brintellix® at the American Psychiatric Association 167th Annual Meeting

H. Lundbeck A/S (Lundbeck) announced today that clinical and pre-clinical data highlighting the company’s ongoing commitment to advancing the science and treatment of depression will be presented at the American Psychiatric Association (APA) 167th Annual Meeting in New York City, USA on 3-7 May 2014.  In total, there will be 13 poster presentations on pre-clinical and clinical data of vortioxetine (Brintellix®), and covering efficacy and tolerability results, both in long term studies as well as across distinct patient populations. The abstracts are embargoed until Saturday, 3 May at 8 AM (EST) and will be posted on the APA website.

Brintellix® was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Major Depressive Disorders in adults and by the European Commission for the treatment of adults with Major Depressive Episodes, commonly referred to as depression. More recently, the Australian Therapeutic Goods Administration (TGA) approved Brintellix® for the treatment Major Depressive Disorders in April 2014.

Clinical data:

Poster NR6-106: A Phase 3, Long-Term, Open-Label Extension Study Evaluating the Safety and Tolerability of vortioxetine in Subjects with Major Depressive Disorder
Authors: Jacobsen PL, Harper L, Serenko M, Chan S, Mahableshwarkar AR.

Poster NR6-105: Which Cognitive Domains are Improved by Treatment with vortioxetine?
Authors: Harrison JE, Lophaven S, Olsen CK.

Poster NR6-112: A Meta-Analysis of the Efficacy of vortioxetine in Patients with Major
Depressive Disorder (MDD) and High Levels of Anxiety Symptoms
Authors: Baldwin DS, Ménard F, Loft H, Chen Y, Mahableshwarkar AR.

Poster NR6-130: Efficacy of vortioxetine vs Placebo in Adults with Major Depressive Disorder:
Meta-Analyses of MADRS Single Items from 9 Short-Term Studies
Authors: Thase ME, Mahableshwarkar AR, Dragheim M, Loft H.

Poster NR6-114: Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of vortioxetine in Adult Patients with Major Depressive Disorder (MDD)
Authors: McIntyre RS, Lophaven S, Olsen CK.

Poster NR6-118: Efficacy and Tolerability of vortioxetine vs agomelatine is independent of Previous Treatment in MDD Patients Switched After an Inadequate Response
Authors: Papakostas G, Nielsen RZ, Dragheim M.

Pre-clinical data:

Poster NR6-086: Vortioxetine: Exploratory Analysis of the Relation Between Target Engagement and Integrated Clinical Database Analysis of Single MADRS Scale Items
Authors: Areberg A, Mahableshwarkar AR, Sánchez C.

Poster NR6-111: Vortioxetine-Induced Recovery of Memory Impairment in Old Mice is Associated with Activation of Synaptic Plasticity Genes But Not Neurogenesis
Authors: Li Y, Abdourahman A, Tamm JA, Sánchez C, Gulinello M.

Poster NR6-132: Role of the Novel Multimodal-Acting Antidepressant vortioxetine in Regulation of Synaptic Marker Expression and Dendritic Branching
Authors: Waller J, Li Y, du Jardin KG, Wegener G, David DJ, Sánchez
Poster NR6-122:  Vortioxetine Produces Acute and Sustained Enhancement of Monoaminergic Neurotransmission through 5-HT Receptor Modulation and 5-HT Transporter Inhibition
Authors: Pehrson A, Sánchez C.

Poster NR6-127: Histamine and Cognition: Chronic Treatment with the Multimodal Acting Antidepressant vortioxetine Activates the Central Histaminergic System in Rats
Authors: Smagin GN, Song D, Budac DP, Pehrson A, Li Y, Sánchez, C.

Poster NR6-125:  Vortioxetine, a Multimodal-Acting Antidepressant with Distinct Pharmacological
Properties – A Comparative Preclinical Study vs. SRIs
Authors: Sánchez C, Dale E, Li Y, Leiser SC, Gulinello M.

Poster NR8-101: Vortioxetine Produces Acute and Sustained Enhancement of Monoaminergic Neurotransmission through 5-HT Receptor Modulation and 5-HT Transporter Inhibition
Authors: Mørk A, Pehrson A, Bétry C, Haddjeri H, Sánchez C.